title: Value of BNP and tumour marker CA125 in patients with heart failure.
abstract: OBJECTIVE
  The objective was to study the association between B-type natriuretic peptide (BNP) and tumour markers and heart failure (HF) to evaluate the value of BNP and carbohydrate antigen 125 (CA125) in HF patients.
  
  
  METHODS
  A university hospital-based cross-over study of 285 subjects (157 men and 128 women) in HF, chronic obstructive pulmonary disease (COPD), mild-mid pulmonary hypertension patients and control subjects.
  
  
  RESULTS
  CA125 and BNP were significantly higher in the HF group than in the non-HF group and in severe HF than in mild HF (P < 0.01). No changes were observed in other tumour markers. CA125 and BNP decreased obviously after clinical improvement by aggressive treatment (P < 0.01). Left ventricular ejection fraction correlated positively with CA125 (r = 0.789, P < 0.01) and BNP (r = 0.730, P < 0.01) in left heart failure patients, but not in other patients. BNP and CA125 had better accuracy and positive predictive value in diagnosing HF from the characteristic receiver-operator curve.
  
  
  CONCLUSIONS
  CA125 and BNP are markedly elevated in heart failure and closely reflect heart function. They are better markers in evaluating the efficiency of short-term therapy. Detecting BNP combined with CA125 may be more valuable than only detecting BNP or CA125 for diagnosing HF and evaluating the efficiency of treatment.
authors.affiliation: Department of Cardiology, the Second Affiliated Hospital of Sun Yat-sen University, Guangzhou Guangdong, People's Republic of China.
authors.forename: Yang-Xin
authors.initials: YX
authors.lastname: Chen
authors.forename: Xiao-Qiao
authors.initials: XQ
authors.lastname: Wang
authors.forename: Chong-Feng
authors.initials: CF
authors.lastname: Fang
authors.forename: Jing-Feng
authors.initials: JF
authors.lastname: Wang
authors.forename: Li-Jiang
authors.initials: LJ
authors.lastname: Tang
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D018394:CA-125 Antigen / Q000097:blood*; D016022:Case-Control Studies; D018592:Cross-Over Studies; D018450:Disease Progression; D005260:Female; D006305:Health Status Indicators; D006333:Heart Failure / Q000097:blood* / Q000000981:diagnostic imaging / Q000503:physiopathology; D006801:Humans; D007297:Inpatients; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D011379:Prognosis; D012372:ROC Curve; D018570:Risk Assessment; D012307:Risk Factors; D013318:Stroke Volume; D014463:Ultrasonography; D016277:Ventricular Function, Left
chemical_list: D015415:Biomarkers; D018394:CA-125 Antigen; D020097:Natriuretic Peptide, Brain